Rayence Co. Ltd - Asset Resilience Ratio
Rayence Co. Ltd (228850) has an Asset Resilience Ratio of 39.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Rayence Co. Ltd's Asset Resilience Ratio has changed over time. Check Rayence Co. Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Rayence Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Rayence Co. Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩104.00 Billion | 39.81% |
| Total Liquid Assets | ₩104.00 Billion | 39.81% |
Asset Resilience Insights
- Very High Liquidity: Rayence Co. Ltd maintains exceptional liquid asset reserves at 39.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rayence Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Rayence Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO |
Medical Devices | 10.80% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Rayence Co. Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Rayence Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.81% | ₩104.00 Billion ≈ $70.48 Million |
₩261.22 Billion ≈ $177.02 Million |
-15.98pp |
| 2024-12-31 | 55.79% | ₩150.21 Billion ≈ $101.79 Million |
₩269.22 Billion ≈ $182.44 Million |
+2.22pp |
| 2023-12-31 | 53.57% | ₩148.65 Billion ≈ $100.74 Million |
₩277.49 Billion ≈ $188.05 Million |
+3.67pp |
| 2022-12-31 | 49.90% | ₩130.73 Billion ≈ $88.59 Million |
₩262.00 Billion ≈ $177.55 Million |
+0.96pp |
| 2021-12-31 | 48.94% | ₩118.33 Billion ≈ $80.19 Million |
₩241.80 Billion ≈ $163.86 Million |
+3.79pp |
| 2020-12-31 | 45.15% | ₩101.45 Billion ≈ $68.75 Million |
₩224.72 Billion ≈ $152.29 Million |
+6.72pp |
| 2019-12-31 | 38.43% | ₩89.18 Billion ≈ $60.43 Million |
₩232.07 Billion ≈ $157.27 Million |
-4.47pp |
| 2018-12-31 | 42.89% | ₩86.27 Billion ≈ $58.46 Million |
₩201.13 Billion ≈ $136.30 Million |
-3.03pp |
| 2017-12-31 | 45.92% | ₩90.21 Billion ≈ $61.13 Million |
₩196.45 Billion ≈ $133.13 Million |
+1.21pp |
| 2016-12-31 | 44.71% | ₩85.12 Billion ≈ $57.68 Million |
₩190.36 Billion ≈ $129.00 Million |
-- |
About Rayence Co. Ltd
Rayence Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and sale of digital X-ray detector products for dental, medical, veterinary, and industrial sectors in South Korea, the United States, Mexico, China, and internationally. The company offers TFT/CMOS X-ray detectors for general radiography, C-arm/RF, mammography, and radiotherapy; and CMOS/Super IGZO TFT/a-… Read more